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Abstract
Background: Systemic hypertension often accompanies chronic renal failure and can accelerate its progression to end-
stage renal disease (ESRD). Adjunctive moxonidine appeared to have benefits versus adjunctive nitrendipine, in a
randomised double-blind six-month trial in hypertensive patients with advanced renal failure. To understand the longer
term effects and costs of moxonidine, a decision analytic model was developed and a cost-effectiveness analysis performed.
Methods: A Markov model was used to extrapolate results from the trial over three years. All patients started in a non-
ESRD state. After each cycle, patients with a glomerular filtration rate below 15 ml/min had progressed to an ESRD state.
The cost-effectiveness analysis was based on the Dutch healthcare perspective. The main outcome measure was
incremental cost per life-year gained. The percentage of patients progressing to ESRD and cumulative costs were also
compared after three years. In the base case analysis, all patients with ESRD received dialysis.
Results: The model predicted that after three years, 38.9% (95%CI 31.8–45.8) of patients treated with nitrendipine
progressed to ESRD compared to 7.5% (95%CI 3.5–12.7) of patients treated with moxonidine. Treatment with standard
antihypertensive therapy and adjunctive moxonidine was predicted to reduce the number of ESRD cases by 81% over three
years compared to adjunctive nitrendipine.
The cumulative costs per patient were significantly lower in the moxonidine group €9,858 (95% CI 5,501–16,174) than in
the nitrendipine group €37,472 (95% CI 27,957–49,478).
The model showed moxonidine to be dominant compared to nitrendipine, increasing life-years lived by 0.044 (95%CI
0.020–0.070) years and at a cost-saving of €27,615 (95%CI 16,894–39,583) per patient.
Probabilistic analyses confirmed that the moxonidine strategy was dominant over nitrendipine in over 98.9% of cases. The
cumulative 3-year costs and LYL continued to favour the moxonidine strategy in all sensitivity analyses performed.
Conclusion: Treatment with standard antihypertensive therapy and adjunctive moxonidine in hypertensive patients with
advanced renal failure was predicted to reduce the number of new ESRD cases over three years compared to adjunctive
nitrendipine. The model showed that adjunctive moxonidine could increase life-years lived and provide long term cost
savings.
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End-stage renal disease (ESRD) is a disorder that occurs
worldwide and is associated with a high cost to society
due to the need for dialysis or renal transplantation. In
1994, 7,340 patients in the Netherlands were receiving
renal replacement therapy, incurring direct medical costs
of NLG 584 million (262 million 1994 €) and indirect
costs of NLG 3.5 million (1.6 million 1994 €). De Wit et
al estimated that in 2003, there would be 11,500 patients
receiving renal replacement therapy at a cost to society of
over NLG 900 million (405 million 1994 €) [1].
Systemic hypertension frequently accompanies chronic
renal failure (CRF) and is a strong risk factor for the devel-
opment of ESRD [2]. Thus current drugs target systemic
hypertension in addition to proteinuria in an attempt to
slow the progression of renal disease [3]. Angiotensin-
converting enzyme inhibitors (ACEI) or angiotensin
receptor blockers (ARB) are the treatment of choice for
hypertensive patients with CRF, with the addition of diu-
retics for inadequate blood pressure control. Patients
often require athird drug to control hypertension effec-
tively [4,5].
Moxonidine may be a good candidate for adjunctive treat-
ment to standard therapy as it interferes with the sympa-
thetic nervous system overactivity [6] which may
contribute to hypertension in CRF patients [6-9].
The short term benefits of adjunctive treatment with mox-
onidine on top of standard antihypertensive therapy have
been shown, versus adjunctive nitrendipine, in a single
randomised double-blind 24-week trial in hypertensive
patients with advanced renal failure. Most patients
received standard therapy of ACEI or ARB plus diuretics.
Although this study was primarily a safety and tolerability
study, a significant difference was seen in creatinine clear-
ance decline between the moxonidine group and the com-
parator group after 24 weeks of treatment [10]. This was
the only study found comparing moxonidine to nitren-
dipine in a review of the literature to date. Creatinine
clearance is an indicator of the glomerular filtration rate of
the kidneys. A reduction in creatinine clearance levels
indicates a decline in kidney function. The trial measured
baseline proteinuria in around 60% of patients in each
group and found levels were similar across both groups.
But proteinuria levels were not available in 40% of
patients and therefore it is not possible to know this
impact on the overall trial outcomes, as proteinuria is a
risk factor for renal disease progression. Therefore a major
assumption of our study was that the differences in creat-
inine clearance decline were not caused by other risk fac-
tors (such as underlying disease or proteinuria level).
Based on this assumption, it was hypothesised that
adjunctive moxonidine in hypertensive patients with
renal failure may contribute to decreasing the burden of
ESRD.
In order to understand the effects of moxonidine on renal
progression and on costs over a longer period, a decision
analytic model was developed and a cost-effectiveness
analysis was performed on the basis of the Dutch health-
care setting.
Methods
Decision-Analytic Model and assumptions
A Markov model was built in MS Excel to extrapolate
results from the six-month trial, of adjunctive moxonidine
versus adjunctive nitrendipine, over three years (or six
cycles of six months). This time horizon of three years
closely approximates the maximum follow-up period of
cohorts of ESRD patients found in the literature [11-14].
In the model, all patients started in a non-ESRD state
(NESRD). NESRD was defined as patients with advanced
renal failure and hypertension, with a glomerular filtra-
tion rate (GFR) above 15 ml/min, not treated with dialysis
or transplant. After each cycle of six months, patients with
a GFR below 15 ml/min were considered to have pro-
gressed to the ESRD state. This cut-off value of 15 ml/min
was based on the European Renal Association (ERA)
guidelines [15] and US National Kidney Foundation
guidelines [16]. Once in the ESRD state, patients could
not go back to the NESRD state, they could either remain
in this state or progress to death. (Figure 1)
Creatinine clearance measures from the trial were not
measured directly, but were obtained using the Cockcroft
& Gault equation, and assumed to equal GFR measures in
the model. The Cockcroft-Gault equation is frequently
The Decision analytic modelFigur  1
The Decision analytic model. Legend  Decision node 
 Markov node ❍ Choice node Ў Terminal node MPage 2 of 8
(page number not for citation purposes)
BMC Nephrology 2007, 8:9 http://www.biomedcentral.com/1471-2369/8/9used for estimating GFR in adults. Although it was origi-
nally developed for estimating creatinine clearance, it has
been widely tested as a good predictor of GFR [17]. Age,
gender, and body weight are used to correct for the differ-
ences in muscle mass, and hence creatinine generation
rate.
Transition probabilities
Transition probabilities for moving from the NESRD
(GFR > 15 ml/min) to ESRD (GFR < 15 ml/min) state
were based on extrapolations of the trial results. The aver-
age GFR decline over the three year time horizon was
assumed to be linear. A linear progression was judged to
be acceptable in these very renally-impaired patients. The
mean decline in GFR over the trial period – from baseline
(visit 2) to week 24 (visit 9) – was 0.7 ml/min for the mox-
onidine group and 1.8 ml/min for the nitrendipine group.
This average decline over a six-month period was applied
to each six-month period in the model, with accompany-
ing standard deviations (SD) keeping the ratio of mean/
SD constant throughout the cycles. Based on the given
and estimated means and SD, the percentage of patients
with ESRD (GFR < 15 ml/min) was then calculated for
each six-month period using the gamma distribution
(parameters Moxonidine α = 1.445, β = 83.555, Nitren-
dipine: α = 12.403, β = 66.597). The gamma distribution
was found to best describe the trial data compared to the
normal or lognormal distribution (skewed to the right
with no negative values) [18,19]. A consequence of this
method is that there were some patients with ESRD at
baseline in both groups, and these patients were not
receiving dialysis or transplants. Therefore only new cases
of ESRD were used to derive transition probabilities for
the model.
For each six-month period: Transition probability = new
cases ESRD/NESRD population (Table 1.)
Transition probabilities for moving from the ESRD state
to Death were based on Dutch mortality rates for patients
on dialysis and transplanted patients. The base case model
assumed all patients were on dialysis. As survival rates
were very different for ESRD patients on dialysis or receiv-
ing transplants, the percentage of patients on each of these
types of renal replacement therapy had to be varied in sen-
sitivity analyses[20]. (Table 1.)
Summary of assumptions
• A time horizon of 3 years approximates the maximum
follow-up period of ESRD patients
• The difference in GFR decline found in the trial was not
caused by differences in other risk factors for decline in
renal function (like underlying disease or proteinuria
level).
• The Cockroft and Gault formula is acceptable to calcu-
late the GFR levels for the population of the study.
• The average decline in GFR over the years can be
described by a linear function
• Extrapolating the average decline found over the initial
6 months will not overestimate the decline in the follow-
ing periods.
• The gamma distribution is best to estimate the percent-
age of patients with a GFR < 15.
• All patients received dialysis during the ESRD state.
• From the NESRD state patients could stay in this state or
enter the ESRD state
• From the ERSD state patients could stay in this state or
enter the death state but they could not go back to the
NESRD state.
Resource use and costs by health state
Costs per cycle for the NESRD state included general med-
ical costs (consultations, diagnostics and laboratory serv-
ices) based on costing data from the economic evaluation
Table 1: Transition probabilities of moving from NESRD state to ESRD state
Cycle NESRD to ESRD† NESRD to Death†† ESRD to Death‡
moxonidine nitrendipine all-cause Dialysis Transplant Dial/Trans 64%/34% Dial/Trans 50%/50%
1 0.019 0.077 0.0042 0.067 0.013 0.048 0.040
2 0.012 0.053 0.0042 0.067 0.013 0.048 0.040
3 0.013 0.069 0.0042 0.067 0.013 0.048 0.040
4 0.014 0.089 0.0042 0.067 0.013 0.048 0.040
5 0.016 0.118 0.0042 0.067 0.013 0.048 0.040
6 0.017 0.157 0.0042 0.067 0.013 0.048 0.040
†Based on data from Vonend et al 2003.
††Based on Dutch all-cause mortality 2005 (8.4 per 1,000 inhabitants), (Centraal Bureau voor de Statistiek)
‡Based on data from ERA EDTA Annual report 2002.Page 3 of 8
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from the trial (moxonidine, nitrendipine and an average
cost of hypertension drugs used) [10]. Diuretic drug costs
were assumed to be covered in the general medical costs.
The ESRD state costs per cycle included costs for dialysis
or transplantation, consultations, general drug, diagnostic
and laboratory services costs based on the economic eval-
uation of ESRD treatments in the Netherlands performed
by the Wit et al[22]. Costs associated with entering the
state Death were based on costs for patients in the termi-
nal phase of ESRD reported by van Hout et al [21]. (Table
2.)
All cost data were expressed in Euros; USD costs were con-
verted to Euro by purchasing power parities [23]. All costs
were transformed to 2004 prices by means of price
indexes from the Dutch "Manual for cost calculations:
methods and recommend prices for economic evalua-
tions in health care." All drug costs were based on public
prices (ex VAT) from the Dutch Z-index. The daily defined
dosage was used to calculate the drug price per cycle.
Generally Markov models assume transitions from one
health state to the next occur at the end of the cycle, how-
ever in reality this transition can occur at any point during
the cycle, therefore a half-cycle correction was incorpo-
rated.
The cost-effectiveness analysis
The cost-effectiveness analysis was based on the Dutch
healthcare perspective, with a time horizon of three years
from the start of treatment. The main outcome measure
was the incremental cost per life-year gained. The percent-
age of patients with ESRD and the cumulative costs were
also compared at three years. A discount rate of 4% on
costs and 1.5% on life-years per annum was applied, as
recommended by the Dutch guidelines [24].
The cost-effectiveness analysis was performed for a hypo-
thetical cohort of patients similar to the patients in the
trial: adult patients with advanced renal failure (GFR < 30
ml/min) and hypertension (DBP 80–100). Patients were
already receiving treatment with loop diuretics and ACEI
or ARB, and were given moxonidine (0.3 mg/day) or
nitrendipine (20 mg/day). Patient exclusion criteria
included presence of sick sinus syndrome, higher degree
sino-atrial or atrioventricular block, bradycardia, malig-
nant arrhythmia, heart failure of New York Heart Associa-
tion stage III or IV, severe chronic ischemic heart disease,
symptomatic cerebrovascular disease, unstable angina
pectoris, severe hepatic disease, history of malignant dis-
ease within two years, pregnancy or lactation, history of
depression, drug abuse or alcoholism.
Scenario Analyses
In the base case analysis, all patients with ESRD were
assumed to receive dialysis treatment, a discount rate was
applied to costs and benefits, a linear decline was assumed
for progression to ESRD and no patients died from the
NESRD state. Scenario analyses were performed to evalu-
ate the effects and costs if:
• 64% of patients received dialysis treatment and 36%
received a transplant (split based on the incidence figures
of the Dutch Renine Registry for 2002 [20])
• or 50% of patients received dialysis and 50% received a
transplant (split based on prevalence figures from the
Dutch Renine Registry 2002 [20])
Both analyses were performed with a 'living donor to
cadaver donor' ratio of 34% to 66% [20].
• 0% discount on costs and benefits was applied
• an exponential decline was used for progression to
ESRD
• all-cause Dutch death rate was applied to patients with
NESRD
Table 2: Breakdown of costs (€) by health state.
Cost components per cycle (6-months) NESRD ESRD First 2 
cycles
ESRD Subsequent 
cycles
Terminal 
ESRD
moxonidine 0.3 mg/d† 82.80 - - -
nitrendipine 20 mg/d† 74.40 - - -
Other antihypertensives† 93.90 - - -
Consultations, diagnostics, laboratory services, diuretics‡ 213.00 - - -
Dialysis including consultations, drugs, diagnostics and laboratory services* - 34,522.00 32,627.00 -
Transplantation including consultations, drugs, diagnostics and laboratory services* - 22,850.00 4,570.00 -
Terminal ESRD care‡ - - - 1,416.00
† z-index: Cost of antihypertensives based on patient usage: 89% on ACE I (ddd enalapril 25 mg) and 11% on ARB (ddd losartan 50 mg), and 35.6% 
on beta blocker (ddd atenolol 75 mg) and 27.4% on alpha blocker (ddd doxazosin 4 mg). Costs of diuretics were assumed to be included in NESRD 
costs based on manuscript van Hout et al.
‡ van Hout et al
* de Wit et alPage 4 of 8
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The source data are characterised by uncertainty. A proba-
bilistic sensitivity analysis was performed to quantify the
uncertainty in the model outcomes. A random value was
repeatedly sampled from distributions reflecting the
uncertainty level of the input source data, plugged into the
model, and then the outcome of the model was calcu-
lated. Each model outcome is presented with a point esti-
mate along with uncertainty reflected by the 2.5 th and
97.5th percentile of the uncertainty distribution. Uncer-
tainty in the transition probabilities from NESRD to ESRD
were based on the trial and expressed with beta distribu-
tions (alpha and beta determined from the standard
error). Uncertainty in resource data were expressed with
triangular distributions, with the low and high values as
80% and 120% of the expected value. Probabilistic sensi-
tivity analysis was performed for both the base case sce-
nario and for scenario analyses.
Results
Effects
The model predicted that after three years, 38.9% (95%CI
31.8–45.8) of patients treated with nitrendipine pro-
gressed to ESRD compared to only 7.5% (95%CI 3.5–
12.7) of patients treated with moxonidine. Thus suggest-
ing that standard treatment with adjunctive moxonidine
could prevent 31.4% of new cases of ESRD compared to
adjunctive nitrendipine (see Figure 2.), or reduce the
number of ESRD cases by 81%.
The proportion of survivors was 98.6% in the moxonidine
group after three years compared to 93.9% in the nitren-
dipine group. Thus the model suggests that patients
treated with moxonidine could gain on average 0.044
(95%CI 0.020–0.070) life-years compared to patients on
nitrendipine (discounted life-years were 2.950 (95%CI
2.937–2.959) versus 2.907 (95%CI 2.882–2.927).
Costs
After three years, the cumulative costs per patient
appeared to be lower in the moxonidine group (€9,858
with 95% CI 5,501–16,174) than in the nitrendipine
group (€37,472 with 95% CI 27,957–49,478) (see Figure
3). Thus moxonidine provided a cost saving of €27,615
(95%CI 16,894–39,583).
Cost-effectiveness
The model calculated that moxonidine treatment pro-
vided a cost saving of €27,615 (95%CI 16,894–39,583)
and extra life-years gained of 0.044 (with 95% CI 0.020–
0.070) years compared to nitrendipine treatment, thus
moxonidine was the dominant strategy. (Table 3) Moxo-
nidine is said to be dominant because it could provide a
more effective treatment strategy and for less cost. Proba-
bilistic sensitivity analyses confirmed that the moxoni-
dine strategy was dominant over nitrendipine in over
98.9% of cases.
Costs and impact of treatment
Thus if 100 patients were given each treatment over three
years, the model predicts that after three years 7 patients
on moxonidine versus 39 on nitrendipine will have pro-
gressed to ESRD, and 1 patient will have died in the mox-
onidine arm versus 6 in the nitrendipine arm. The cost of
treating the moxonidine group would be €985,800 versus
€3,747,200 for the nitrendipine group, due to the high
cost of treating patients who have progressed to ESRD.
Scenario analyses
The proportion of ESRD patients receiving dialysis or
transplantations was varied in sensitivity analyses. The
Expected 3-year cumulative cost per patientFigure 3
Expected 3-year cumulative cost per patient.
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sis (and 34% received transplantations), the cumulative 3-
year costs remained lower with moxonidine versus nitren-
dipine (€8,496 (95% CI 4,920–13,367) versus €31,035
(95% CI 23,618–40,163) respectively), and life-years
remained higher in the moxonidine arm (2.954 (95% CI
2.944–2.960) versus 2.923 (95% CI 2.907–2.936) respec-
tively). When 50% of patients received dialysis (and 50%
transplantation), the cumulative 3-year costs and LYL con-
tinued to favour the moxonidine strategy versus nitren-
dipine (€7,953 (95% CI 4,603–12,546) and 2.955
(95%CI 2.946–2.960) for moxonidine versus €28,649
(95% CI 21,938–36,392) and 2.929 (95% CI 2.915–
2.941) for nitrendipine).
When a 0% discount rate was applied to costs and effects
the following results were found: Cumulative costs were
€10,349 (95%CI 5,572–17,282) with moxonidine and
€39,035 (95% CI 29,324–50,003) with nitrendipine,
resulting in a cost saving of €28,686 (95% CI 17,772–
41,347) with moxonidine. Life-years lived were 2.987
(95% CI 2.971–2.996) for moxonidine and 2.943 (95%
CI 2.919–2.963) for nitrendipine, resulting in 0.044
(95% CI 0.019–0.070) life-years gained with moxoni-
dine.
When the average GFR decline was assumed to decrease
exponentially, the results still supported moxonidine over
nitrendipine; all patients on nitrendipine had progressed
to ESRD after 2 years versus 25% of patients on moxoni-
dine (or 74% after 3 years). Thus moxonidine would pro-
vide 0.084 (95%CI 0.059–0.108) additional life-years at a
cost saving of €48,364 (95%CI 37,966–59,198) after 3
years.
When Dutch all-cause mortality was incorporated to the
NESRD arm, the life-years gained with moxonidine was
0.041 (95%CI -0.035–0.112) years at a cost saving of
€27,252 (95%CI 16,652–38,854). Moxonidine was dom-
inant in 90% of cases.
Discussion
With this model, moxonidine treatment on top of stand-
ard therapy in severely renally-impaired patients appears
to be cost-effective versus adjunctive nitrendipine, result-
ing in lower treatment costs (€27,615 lower (95%CI
16,894–39,583)) and a greater number of life-years lived
0.044 (with 95% CI 0.020–0.070) when the results of the
six month trial are extrapolated over three years. Sensitiv-
ity analyses have shown that these results are robust. Thus
given the assumptions of the model, we can conclude that
moxonidine could delay progression to ESRD in a large
number of patients, thereby reducing the numbers of
patients requiring dialysis or transplants compared to
standard treatment with adjunctive nitrendipine. Treat-
ment with moxonidine could therefore contribute to
reducing the economic burden of ESRD and allow
patients to live longer in a non-ESRD state.
Limitations of the model
Data used in the model was taken from the only study
available at the time of moxonidine versus nitrendipine,
which was a six-month trial, in 171 patients, with pro-
teinuria levels measured in 103 patients. In the trial, cre-
atinine clearance was calculated using the Cockcroft &
Gault equation. As creatinine clearance is the result of
clearance due to GFR and secretion of creatinine in the
tubules, the model assumed that both treatments had no
effect on secretion, thus GFR was equated to creatinine
clearance measures alone.
The difference in GFR decline in the trial was assumed not
to be due to differences in risk factors for renal progres-
sion such as level of proteinuria like albuminuria. Data on
albuminuria were only available for a subset of patients in
the trial (52/89 moxonidine patients and 51/82 nitren-
dipine patients). These data showed no significant differ-
ences between groups, although mean and median
albuminuria values were lower in the moxonidine group
(1.3 ± 1.8; 0.8 versus 1.9 ± 2.1; 1.1 at baseline). A limita-
tion of this study is that the missing data for the remaining
patients may mean that the two groups were not well
matched for albuminuria, a major prognostic factor for
renal decline [10].
The average GFR decline over the three year time horizon
was assumed to be linear. This is not uncommon in the lit-
erature [25-27]. The extrapolation of GFR values from the
six month trial also implied that the decline in the first
three months after starting treatment was not significantly
different than the decline in the following periods, as is
sometimes suggested in the literature [18]. However some
clinicians assume an exponential decline over time. If the
decline is exponential, and disease progression occurs
faster, the benefit of moxonidine will be even greater as it
appears to delay progression compared to nitrendipine.
Table 3: Results of the base case model after 3 years
% progress to ESRD (95%CI) Life years lived (95%CI) Costs (€) (95%CI)
Moxonidine 7.5% (3.5–12.7) 2.950 (2.937–2.959) €9,858 (5,501–16,174)
Nitrendipine 38.9% (31.8–45.8) 2.907 (2.882–2.927) €37,472 (27,957–49,478)Page 6 of 8
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BMC Nephrology 2007, 8:9 http://www.biomedcentral.com/1471-2369/8/9The results of the scenario analysis show that all nitren-
dipine patients would have progressed to ESRD compared
to 25% of moxonidine patients after two years.
The model only included direct costs. The addition of
indirect costs would however be expected to increase the
benefit seen with moxonidine, as patients remain in a bet-
ter state of health for longer and are therefore able to be
more productive.
Patients with ESRD are presumed to have much worse
quality of life than patients at earlier stages of the disease.
Utility values found in the literature report measures of
0.41 for patients on kidney dialysis [28] compared to 0.60
for patients with chronic renal failure [29]. A higher utility
value is associated with a better state of health. As such, a
cost-utility analysis would be expected to produce even
better results for moxonidine compared to standard treat-
ment with nitrendipine, as patients treated with moxoni-
dine remained in a non-ESRD state for longer.
Adjunctive treatment with moxonidine was assumed to
have a renoprotective effect occurring independently of
blood pressure control in the six month trial. This effect
may be supported by the results of a recent study in which
moxonidine was the only factor that significantly reduced
the risk of a decrease of 50% or more in creatinine clear-
ance rate, or the need for dialysis, or death, in patients fol-
lowing renal transplant. The relative risk reduction due to
moxonidine was 0.3 (95% CI 0.1 – 0.6) in the multivari-
ate analysis [30]. Results of a small study in the Nether-
lands may also support the benefits of adjunctive
moxonidine in chronic renal failure. In this study, moxo-
nidine normalised sympathetic hyperactivity, which plays
a role in renal hypertension, in patients on chronic epro-
sartan treatment [19].
Conclusion
The model extrapolated results from a 6-month trial over
three years. Treatment with standard antihypertensive
therapy (ACE inhibitor or ARB and loop diuretics) and
adjunctive moxonidine in hypertensive patients with
advanced renal failure was predicted to reduce the
number of ESRD cases by 81% over three years compared
to adjunctive nitrendipine. The model showed moxoni-
dine to be dominant compared to nitrendipine, increas-
ing life-years lived by 0.044 (95%CI 0.020–0.070) years
and at a cost-saving of €27,615 (95%CI 16,894–39,583)
per patient.
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